ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
July 31 2019 - 4:05PM
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a
conference call on Wed., August 7, 2019 at 4:30 p.m.
Eastern time to discuss its financial results for the second
quarter ended June 30, 2019. The financial results will be
reported in a press release after the close of regular stock market
trading hours on the same day as the conference call.
Investor Conference Call:
ChromaDex management will host an investor
conference call to discuss the second quarter results and provide a
general business update on Wed., August 7, at 4:30 p.m.
ET.
Participants should call in at least 10 minutes
prior to the call. The dial-in information is as follows:
Date: Wed., August 7, 2019 Time: 4:30 p.m. Eastern
time (1:30 p.m. Pacific time) Toll-free dial-in number:
1-866-211-3191 International dial-in number: 1-647-689-6604
Conference ID: 3774159 Webcast link: ChromaDex Q2 2019
Earnings Conference Call
The conference call will be broadcast live and
available for replay here and via the investor relations
section of the Company’s website at www.chromadex.com.
A replay of the conference call will be
available after 7:30 p.m. ET.
Toll-free replay number: 1-800-585-8367 International replay
number: 1-416-621-4642 Replay ID: 3774159
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people
age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly
to consumers as TRU NIAGEN®, is backed with clinical and
scientific research, as well as extensive IP protection. TRU
NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website
at www.chromadex.com to
which ChromaDex regularly posts copies of its press
releases as well as additional and financial information about the
Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website
at www.sec.gov. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and actual results may differ materially from
those suggested by these forward-looking statements. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ChromaDex undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof.
ChromaDex Investor Relations Contact: Brianna
Gerber, Senior Director of FP&A and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex Media Contact: Alex Worsham, Director
of Strategic Partnerships 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Corporation
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024